<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054910</url>
  </required_header>
  <id_info>
    <org_study_id>F130822012</org_study_id>
    <nct_id>NCT02054910</nct_id>
  </id_info>
  <brief_title>CPB Versus Sham Treatment for Pain Management in Small Duct Chronic Pancreatitis</brief_title>
  <official_title>Randomized Single Blinded Control Trial Comparing EUS Guided Celiac Plexus Block (CPB) Versus Sham Treatment for Pain Management in Small Duct Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the pain response to Endoscopic Ultrasound (EUS) guided Celiac Plexus
      Block (CPB) treatment in comparison to EUS without a pain block administered. All
      participants will receive medications for pain as needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess pain response to EUS guided celiac plexus block
      treatment compared to no treatment. The Visual Analog Scale (VAS) is the primary measure.
      Secondary aims include the comparison of quality of life scores, need for narcotics, to
      assess the effect of EUS-CPB on overall mental state using the Beck's Depression Index, and
      to assess the effect of EUS-CBP on health care utilization and on employment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Response Over a 6 Month Period of Time Using the VAS Score</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Pain scores will be assessed by comparing the mean number change using the Visual Analog Scale (VAS) from baseline to 6 month. The scale is 10 - 0, with 10 being agonizing pain and 0 being no pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Quality of Life Score Between Each Group at 6 Months</measure>
    <time_frame>6 months post baseline</time_frame>
    <description>The American Chronic Pain Association, Quality of Life Score will be used. This scoring ranges from 0 (Stay in bed all day Feel hopeless and helpless about life - non-functioning) to 10 (Go to work/volunteer each day Normal daily activities each day Have a social life outside of work Take an active part in family life - normal life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subject in Each Group Requiring Administration of Narcotics During 6 Months Post Baseline</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>the number of subjects receiving a narcotic drug during the 6 months post baseline will be noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Mental State Between Groups Using the Beck's Depression Index at 6 Months.</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>The Beck's Depression scale was used to indicate subject's depression:
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Times Subjects in Each Group Accessed the Health Care System Within 6 Months Post Procedure</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>The number of times each subject accessed the health care system will be collected, and then the mean will be calculated for each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Subjects in Each Group That Are Employed at 6 Months Post Procedure.</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Subjects will be asked about employment at 6 months post procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Celiac Plexus Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celiac Plexus Block will be administered following EUS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A celiac plexus block will not be administered for pain management</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Celiac Plexus Block</intervention_name>
    <description>Patients will receive celiac plexus block during endoscopy.</description>
    <arm_group_label>Celiac Plexus Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Patients will not receive celiac plexus block during endoscopy.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients referred to UAB Endoscopy Unit for with known chronic pancreatitis

          -  Patients referred to the endoscopy unit with abdominal pain with suspicion of chronic
             pancreatitis meeting 5 of 9 parenchymal and ductal changes (i.e. lobulations,
             hyperechoic stranding, hyperechoic foci, cysts, calcification, irregular duct,
             hyperechoic walls, side branch dilations and ductal calculi).

        Exclusion Criteria:

          -  Age &lt;19 years

          -  Unable to safely undergo EUS for any reason

          -  Coagulopathy (INR &gt;1.6, Prothrombin Time &gt;18secs, Thrombocytopenia &lt;80,000 cells/ml)

          -  Unable to consent

          -  Non-English speaking patients.

          -  Previously undergone CPB

          -  Pregnancy and Breast feeding

          -  Patients with ductal strictures, calcification, pancreatic ductal calculi,
             pseudocysts.

          -  Previous pancreatic surgery

          -  Previous pseudocyst drainage

          -  Other documented causes of abdominal pain.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M Wilcox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <results_first_submitted>April 22, 2016</results_first_submitted>
  <results_first_submitted_qc>January 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2017</results_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Charles Mel Wilcox, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Celiac Plexus Block</title>
          <description>Celiac Plexus Block will be administered following EUS
Celiac Plexus Block</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>A celiac plexus block will not be administered for pain management
Sham</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Celiac Plexus Block</title>
          <description>Celiac Plexus Block will be administered following EUS
Celiac Plexus Block</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>A celiac plexus block will not be administered for pain management
Sham</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Response Over a 6 Month Period of Time Using the VAS Score</title>
        <description>Pain scores will be assessed by comparing the mean number change using the Visual Analog Scale (VAS) from baseline to 6 month. The scale is 10 - 0, with 10 being agonizing pain and 0 being no pain.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>All subjects were lost to follow up by 6 months; the primary endpoint was not collected for any subject</population>
        <group_list>
          <group group_id="O1">
            <title>Celiac Plexus Block</title>
            <description>Celiac Plexus Block will be administered following EUS
Celiac Plexus Block</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>A celiac plexus block will not be administered for pain management
Sham</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Response Over a 6 Month Period of Time Using the VAS Score</title>
          <description>Pain scores will be assessed by comparing the mean number change using the Visual Analog Scale (VAS) from baseline to 6 month. The scale is 10 - 0, with 10 being agonizing pain and 0 being no pain.</description>
          <population>All subjects were lost to follow up by 6 months; the primary endpoint was not collected for any subject</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Quality of Life Score Between Each Group at 6 Months</title>
        <description>The American Chronic Pain Association, Quality of Life Score will be used. This scoring ranges from 0 (Stay in bed all day Feel hopeless and helpless about life - non-functioning) to 10 (Go to work/volunteer each day Normal daily activities each day Have a social life outside of work Take an active part in family life - normal life).</description>
        <time_frame>6 months post baseline</time_frame>
        <population>All subjects were lost to follow up by 6 months; the secondary endpoint was not collected for any subject</population>
        <group_list>
          <group group_id="O1">
            <title>Celiac Plexus Block</title>
            <description>Celiac Plexus Block will be administered following EUS
Celiac Plexus Block</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>A celiac plexus block will not be administered for pain management
Sham</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Quality of Life Score Between Each Group at 6 Months</title>
          <description>The American Chronic Pain Association, Quality of Life Score will be used. This scoring ranges from 0 (Stay in bed all day Feel hopeless and helpless about life - non-functioning) to 10 (Go to work/volunteer each day Normal daily activities each day Have a social life outside of work Take an active part in family life - normal life).</description>
          <population>All subjects were lost to follow up by 6 months; the secondary endpoint was not collected for any subject</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subject in Each Group Requiring Administration of Narcotics During 6 Months Post Baseline</title>
        <description>the number of subjects receiving a narcotic drug during the 6 months post baseline will be noted.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>All subjects were lost to follow up by 6 months; the secondary endpoint was not collected for any subject</population>
        <group_list>
          <group group_id="O1">
            <title>Celiac Plexus Block</title>
            <description>Celiac Plexus Block will be administered following EUS</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>A celiac plexus block will not be administered for pain management</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject in Each Group Requiring Administration of Narcotics During 6 Months Post Baseline</title>
          <description>the number of subjects receiving a narcotic drug during the 6 months post baseline will be noted.</description>
          <population>All subjects were lost to follow up by 6 months; the secondary endpoint was not collected for any subject</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Mental State Between Groups Using the Beck's Depression Index at 6 Months.</title>
        <description>The Beck's Depression scale was used to indicate subject's depression:
0–9: indicates minimal depression 10–18: indicates mild depression 19–29: indicates moderate depression 30–63: indicates severe depression.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>All subjects were lost to follow up by 6 months; the secondary endpoint was not collected for any subject</population>
        <group_list>
          <group group_id="O1">
            <title>Celiac Plexus Block</title>
            <description>Celiac Plexus Block will be administered following EUS</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>A celiac plexus block will not be administered for pain management</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Mental State Between Groups Using the Beck's Depression Index at 6 Months.</title>
          <description>The Beck's Depression scale was used to indicate subject's depression:
0–9: indicates minimal depression 10–18: indicates mild depression 19–29: indicates moderate depression 30–63: indicates severe depression.</description>
          <population>All subjects were lost to follow up by 6 months; the secondary endpoint was not collected for any subject</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Times Subjects in Each Group Accessed the Health Care System Within 6 Months Post Procedure</title>
        <description>The number of times each subject accessed the health care system will be collected, and then the mean will be calculated for each group</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>All subjects were lost to follow up by 6 months; since everyone dropped out at different times before the 6 month point, the data would not be evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Celiac Plexus Block</title>
            <description>Celiac Plexus Block will be administered following EUS</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>A celiac plexus block will not be administered for pain management</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Times Subjects in Each Group Accessed the Health Care System Within 6 Months Post Procedure</title>
          <description>The number of times each subject accessed the health care system will be collected, and then the mean will be calculated for each group</description>
          <population>All subjects were lost to follow up by 6 months; since everyone dropped out at different times before the 6 month point, the data would not be evaluable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Subjects in Each Group That Are Employed at 6 Months Post Procedure.</title>
        <description>Subjects will be asked about employment at 6 months post procedure</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>All subjects were lost to follow up by 6 months; the secondary endpoint was not collected for any subject</population>
        <group_list>
          <group group_id="O1">
            <title>Celiac Plexus Block</title>
            <description>Celiac Plexus Block will be administered following EUS</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>A celiac plexus block will not be administered for pain management</description>
          </group>
        </group_list>
        <measure>
          <title>% of Subjects in Each Group That Are Employed at 6 Months Post Procedure.</title>
          <description>Subjects will be asked about employment at 6 months post procedure</description>
          <population>All subjects were lost to follow up by 6 months; the secondary endpoint was not collected for any subject</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24-48 hour, 2 week, 6 month, 12 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Celiac Plexus Block</title>
          <description>Celiac Plexus Block will be administered following EUS
Celiac Plexus Block</description>
        </group>
        <group group_id="E2">
          <title>Sham</title>
          <description>A celiac plexus block will not be administered for pain management
Sham</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jaypal Ramesh</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-975-9564</phone>
      <email>jramesh@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

